TY - JOUR
T1 - The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis
AU - Dardiotis, Efthimios
AU - Aloizou, Athina Maria
AU - Siokas, Vasileios
AU - Patrinos, George P.
AU - Deretzi, Georgia
AU - Mitsias, Panayiotis
AU - Aschner, Michael
AU - Tsatsakis, Aristidis
N1 - Funding Information:
MA was supported by grants from the National Institute of Environmental Health Sciences, NIEHS R01ES07331, NIEHS R01ES10563, and NIEHS R01ES020852.
Publisher Copyright:
© Springer Science+Business Media, LLC, part of Springer Nature 2018.
PY - 2018/12
Y1 - 2018/12
N2 - Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.
AB - Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.
KW - Amyotrophic lateral sclerosis
KW - Biomarker
KW - Epigenetics
KW - MicroRNA
KW - Neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=85056322066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056322066&partnerID=8YFLogxK
U2 - 10.1007/s12031-018-1204-1
DO - 10.1007/s12031-018-1204-1
M3 - Article
C2 - 30415446
AN - SCOPUS:85056322066
SN - 0895-8696
VL - 66
SP - 617
EP - 628
JO - Molecular and Chemical Neuropathology
JF - Molecular and Chemical Neuropathology
IS - 4
ER -